HCV Treatment
New Hepatitis C Treatments Highlighted at Digestive Disease Week
- Details
- Category: Experimental HCV Drugs
- Published on Tuesday, 06 May 2014 00:00
- Written by Liz Highleyman
Direct-acting antiviral agents for hepatitis C were a key theme of Digestive Disease Week 2014, taking place this week in Chicago. While the conference covers all aspects of gastroenterology and hepatology, new treatments that can cure more than 90% of chronic hepatitis C patients with few side effects in as little as 8 to 12 weeks are bringing about a revolution in the field.
EASL 2014: Idenix Hepatitis C Drugs Look Promising in Early Studies
- Details
- Category: Experimental HCV Drugs
- Published on Tuesday, 06 May 2014 00:00
- Written by HIVandHepatitis.com
Idenix Pharmaceuticals' hepatitis C virus NS5A inhibitor samatasvir (formerly IDX179) plus Janssen's HCV protease inhibitor simeprevir (Olysio) and ribavirin produced early sustained virological response rates of about 80% in a small study presented at the 49th EASL International Liver Congress last month in London. Another study showed that the company's HCV polymerase inhibitor candidate IDX21437 looks good in preclinical studies and is a potential once-daily partner for samatasvir in interferon-free regimens.
EASL 2014: Sofosbuvir + Ribavirin Is Safe and Effective for HCV Recurrence after Liver Transplant
- Details
- Category: HCV Treatment
- Published on Friday, 02 May 2014 00:00
- Written by Liz Highleyman
An interferon-free combination of sofosbuvir (Sovaldi) plus ribavirin taken for up to 24 weeks led to sustained virological response in 70% of liver transplant recipients with hepatitis C virus (HCV) recurrence, according to a poster presented at the 49thEASL International Liver Congress (EASL 2014) held recently in London.
May Is Hepatitis Awareness Month
- Details
- Category: HBV Treatment
- Published on Friday, 02 May 2014 00:00
- Written by HIVandHepatitis.com
May is Hepatitis Awareness Month in the U.S., an opportunity to promote better understanding of viral hepatitis and to encourage more people to get tested and receive care for hepatitis B and C. Hepatitis Testing Day is coming up on May 19.
EASL 2014: VX-135 + Daclatasvir Shows Modest Cure Rate in Phase 2 Study
- Details
- Category: HCV Treatment
- Published on Friday, 02 May 2014 00:00
- Written by Liz Highleyman
Treatment with an interferon-free regimen of daclatasvir plus VX-135 for 12 weeks was safe and well-tolerated for genotype 1 chronic hepatitis C patients, but the sustained virological response rate of 83% for easier-to-treat patients did not stand up well to cure rates of 90% or higher seen with other similar combinations, according to a late-breaker poster presented at the 49thEASL International Liver Congress held recently in London.
More Articles...
- Achillion Announces Start of Studies of ACH-3422 and ACH-3102 for Hepatitis C
- EASL 2014: Sustained Response to Treatment Reduces Fatigue in Hepatitis C Patients
- EASL 2014: Sofosbuvir + Ribavirin for 24 Weeks Is Highly Effective Against HCV Genotype 4
- AbbVie Requests FDA Approval of Interferon-free "3D" Combo for Hepatitis C
Web Design and Development by